<DOC>
	<DOCNO>NCT00574366</DOCNO>
	<brief_summary>RATIONALE : Erlotinib everolimus may stop growth tumor cell block enzymes need cell growth . Giving erlotinib together everolimus may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose give erlotinib together everolimus see well work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Erlotinib Everolimus Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety everolimus give combination erlotinib hydrochloride patient metastatic breast cancer ( phase I ) . - To determine antitumor activity combination ( phase II ) . - Determine rate clinical benefit ( complete response + partial response + stable disease least 6 month ) patient metastatic breast cancer ( phase II ) . Secondary - To determine time progression . - To determine PTEN , pAkt , pP70S6K1 pEGFR primary tumor baseline . OUTLINE : This open-label , dose escalation phase I study follow open-label phase II study . - Phase I : Patients receive escalate dos oral everolimus oral erlotinib hydrochloride daily maximum tolerate dose ( MTD ) determine . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Once MTD reach , recommend dose use phase II portion study identify . - Phase II : Patients receive oral everolimus oral erlotinib hydrochloride phase I recommend phase II dose determine phase I . Patients undergo tissue collection evaluate tumor level PTEN , pAkt , pP70S6K1 , pEGFR baseline order identify predictor therapeutic response . After completion study treatment , patient follow every 3 month 2 year ( study entry ) , every 6 month 3 year , annually thereafter . NOTE : Phase I complete . Investigator proceed Phase II</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Protein Kinase Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Evaluable metastatic disease ( need measurable disease ) Must anthracycline therapy adjuvant setting fail anthracycline treatment metastatic setting Total cumulative dose lifetime exposure doxorubicin great 360 mg/m^2 epirubicin great 640 mg/m^2 Must fail previous taxane ( paclitaxel docetaxel ) therapy , define : Taxane use adjuvant set metastatic relapse within 12 month therapy Progression taxane therapy metastatic set Discontinuation taxane therapy metastatic setting secondary lack resolution ≥ grade 2 toxicity No symptomatic brain metastasis Patients history brain metastasis eligible provide clinically stable take steroids therapeutic anticonvulsant CYP3A4 modifier Patients asymptomatic brain metastasis eligible provide prophylactic anticonvulsant CYP3A4 modifier Hormone receptor status specify PATIENT CHARACTERISTICS : Inclusion criterion Menopausal status specify ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT SGPT ≤ 2.5 time ULN Albumin &gt; 30 g/L Creatinine ≤ 1.5 upper limit normal INR normal provide patient warfarin therapy Not pregnant nursing Negative pregnancy test premenopausal patient Fertile patient must use effective barrier method contraception 3 month completion study treatment Patients must diseasefree prior invasive cancer &gt; 5 year exception basal cell squamous cell cancer skin cervical carcinoma situ Exclusion criterion Serious nonhealing active wound , ulcer , bone fracture Known human immunodeficiency virus positivity Uncontrolled intercurrent illness include , limited , follow Ongoing active infection require parenteral antibiotic Impairment lung function ( COPD , lung condition require oxygen therapy ) Symptomatic congestive heart failure ( New York Heart Association class III IV heart disease ) Unstable angina pectoris myocardial infarction within past 6 month Uncontrolled hypertension ( i.e. , systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 100 mm Hg , find two consecutive measurement separate 1week period despite adequate medical support ) Clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment ) Uncontrolled diabetes Psychiatric illness/social situation would compromise patient safety limit compliance study requirement include maintenance compliance/pill diary PRIOR CONCURRENT THERAPY : Inclusion criterion See Disease Characteristics Prior trastuzumab ( Herceptin® ) firstline treatment metastatic breast cancer require patient HER2/neu overexpressing tumor More 6 month since prior cardiac angioplasty stenting Use endocrine therapy ( i.e. , aromatase inhibitor , fulvestrant , tamoxifen ovarian ablation ) firstline treatment metastatic breast cancer require patient estrogen receptor progesterone receptor express tumor Concurrent endocrine therapy allow Patients may receive concurrent radiotherapy painful bone metastasis area impend bone fracture long radiotherapy initiate prior study entry Patients receive prior radiotherapy must recover toxicity induce treatment More 3 week since prior chemotherapy , biological hormonal therapy protocol therapy . No concurrent antineoplastic antitumor agent , include chemotherapy , radiotherapy , immunotherapy , hormonal anticancer therapy Exclusion criterion More 3 prior chemotherapy treatment metastatic set This restriction include endocrine therapy single agent biologic therapy ( i.e. , trastuzumab [ Herceptin® ] ) Use steroids immunosuppressant Use CYP3A4 modifier Concurrent therapy trastuzumab ( Herceptin® ) Use growth support factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , recombinant erythropoietin ) phase I portion study Other concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>